CV Sciences Q3: Revenue Stable Amid New Launches, Financing
CV Sciences, Inc. (OTCQB:CVSI), a hemp-focused wellness company, announced stable revenue in its Q3 2024 financials on Thursday. The company generated $3.9 million in revenue, a slight decline from $4.1 million in Q3 2023, yet maintained a gross margin of 46%, up from 45.1% the previous year.
Q3 2024 Financial Highlights
- Revenue: $3.9 million, a 5% decline from $4.1 million in Q3 2023 and stable compared to $4 million in Q2 2024.
- Net loss: $456,000, slightly higher than the $447,000 loss in Q3 2023.
- Adjusted EBITDA: Loss of $75,000, significantly improved from a loss of $361,000 in Q3 2023.
- Gross profit: $1.78 million, a slight decrease from $1.84 million in Q3 2023, reflecting an improved gross margin of 46%, up from 45.1% in the same period last …